A simple and rapid entry to 5-alkyl (aryl)-5-hydroxy-3,4-diarylfuranones and 3a-hydroxy-1-aryl-2,3a,4,5-tetrahydronaphthofuranones via a tandem esterification and oxidative cyclization process

Tetrahedron Letters

Volumn 43, Issue 48, 2002, Pages 8715-8719

  Padakanti, Srinivas ^a   Veeramaneni, Venugopal Rao ^a   Pattabiraman, Vijaya Raghavan ^a   Pal, Manojit ^a   Yeleswarapu, Koteswar Rao ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

bromoketone; 5 hydroxyfuranone; Esterification; Oxidative cyclization; Phenylacetic acid

Indexed keywords

ACETIC ACID DERIVATIVE; ALPHA BROMOKETONE; FURANONE DERIVATIVE; KETONE DERIVATIVE; OXYGEN; UNCLASSIFIED DRUG;

ARTICLE; CYCLIZATION; DRUG OXIDATION; DRUG SYNTHESIS; ESTERIFICATION; REACTION ANALYSIS; REACTION TIME;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0037175469     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(02)02144-5     Document Type: Article

References (36)

1. He H., Kulanthaivel P., Baker B.J. Tetrahedron Lett. 35:1994;7189-7192.
2. Schmidt E.W., Faulkner D. Tetrahedron Lett. 37:1996;3951-3954.
3. Gunasekera S.P., McCarthy P.J., Kelly-Borges M., Lobkovsky E., Clardy J. J. Am. Chem. Soc. 118:1996;8759-8760.
4. Lee G.C.M., Syage E.T., Harcourt D.A., Holmes J.M., Grast M.E. J. Org. Chem. 56:1991;7007-7014.
5. Doherty A.M. Drug Discovery Today. 1:1996;60-70.
6. de Silva E.D., Scheuer P.J. Tetrahedron Lett. 21:1980;1611-1614.
7. Potts B.C.M., Faulkner D.J., De Carvalho M.S., Jacobs R.S. J. Am. Chem. Soc. 114:1992;5093-5100.
8. Doherty A.M., Patt W.C., Edmunds J.J., Berryman K.A., Reisdorph B.R., Plummer M.S., Shahripour A., Lee C., Cheng X.-M., Walker D.M., Haleen S.J., Keiser J.A., Flynn M.A., Welch K.M., Hallak H., Taylor D.G., Reynolds E.E. J. Med. Chem. 38:1995;1259-1263.
9. Suzuki N., Nakaniski J. Chemosphere. 21:1990;387-392.
10. Jinqu Z., Zhen Z., Huixian Z., Minmin Y. Synth. Commun. 25:1995;3401-3405.
11. Takabe, K.; Yoda, H.; Iwabuchi, M.; Tanaka, M. Jpn. Kokai Tokkyo Koho JP 02218673, 31 Aug 1990, 5 pp. Chem. Abstr. 114:61913
12. Takabe, K.; Yoda, H. Jpn. Kokai Tokkyo Koho JP 02311471, 27 Dec 1990, 5 pp. Chem. Abstr. 115:29102
13. Black, C.; Grimm, E.; Wang, Z.; Leger, S. World Patent WO 9636623 A1, 21 Nov 1996, Chem. Abstr. 126:89250
14. Pal, M.; Rao, Y. K.; Rajagopalan, R.; Misra, P.; Kumar, P. M.; Rao, C. S. World Patent WO 01/90097, 29 Nov 2001, Chem. Abstr. 2002, 136, 5893.
15. Halpin R.A., Geer L.A., Zhang K.E., Marks T.M., Dean D.C., Jones A.N., Melillo D., Doss G., Vyas K.P. Drug Metab. Dispos. 28:2000;1244-1254.
16. Nicoll-Griffith D.A., Yergey J.A., Trimble L.A., Silva J.M., Li C., Chauret N., Gauthier J.Y., Grimm E., Leger S., Roy P., Therien M., Wang Z., Prasit P., Zamboni R., Young R.N., Brideau C., Chan C.-C., Mancini J., Riendeau D. Bioorg. Med. Chem. Lett. 10:2000;2683-2686.
17. Kernan M.R., Faulkner D.J. J. Org. Chem. 53:1988;2773-2776.
18. Pommier A., Kocienski P.J. Chem. Commun. 1997;1139-1140.
19. Soriente A., De Rosa M., Scettri A., Sodano G. Tetrahedron Lett. 37:1996;8007-8010.
20. Piers E., Wai J.S.M. Can. J. Chem. 72:1994;146-157.
21. Katsumura S., Inagaki Y., Tsujino K., Han Q. Chem. Lett. 1993;351-352.
22. Boukouvalas J., Lachance N. Synlett. 1998;31-32.
23. Monflier E., Pellegrini S., Mortreux A., Petit F. Tetrahedron Lett. 32:1991;4703-4704.
24. Takabe, K.; Yoda, H.; Tanaka, M.; Sugimoto, M.; Ishioka, T.; Miyazaki, A. Jpn. Kokai Tokkyo Koho JP 02218672, 31 Aug 1990, 5 pp. Chem. Abstr. 114:42558
25. Lardelli G., Dijkstra P., Harkes D., Boldingh J. Rec. Trav. Chim. 85:1966;43.
26. Black, C.; Grimm, E.; Wang, Z.; Leger, S. World Patent WO 9636623, 21 Nov 1996, 109 pp., Chem. Abstr. 126:89250.
27. Pal, M.; Rao, V. V.; Srinivas, P.; Murali, N.; Akhila, V.; Premkumar, M.; Rao, C. S.; Misra, P.; Ramesh, M.; Rao, Y. K. Indian J. Chem. 2002, in press. Srinivas, P.; Pal, M.; Rao, Y. K. Synth. Commun., submitted.
28. Pattabiraman V.R., Padakanti P.S., Veeramaneni V.R., Pal M., Yeleswarapu K.R. Synlett. 2002;947-951.
29. Pal, M.; Rao, V. V.; Rao, Y. K. Presented at the symposium on Current Perspectives in Organic Chemistry (CPOC-2002), Indian Association for the Cultivation of Science, Kolkata, India, 24-25 January, 2002; Paper number 6.
30. 3S requires C, 70.98; H, 5.36%.
31. α-Bromoketones were prepared via Friedel-Crafts acylation of the appropriate arene followed by bromination of the resulting ketone according to the similar procedure described in the literature. See for example: (a) Giordano, C.; Casagrande, F. Ger. Offen. DE 3006277, 4 Sep 1980, 26 pp, Chem. Abstr. 94:30372; (b) Carter, J. S.; Rogier, D. J.; Graneto, M. J.; Seibert, K.; Koboldt, C. M.; Zhang, Y.; Talley, J. Bioorg. Med. Chem. Lett. 1999, 9, 1167-1170.; (c) Almansa, C.; de Arriba, A. F.; Cavalcanti, F. L.; Gomez, L. A.; Miralles, A.; Merlos, M.; Garcia-Rafanell, J.; Forn, J. J. Med. Chem. 2001, 44, 350-361.
32. α-Bromoketones were prepared via Friedel-Crafts acylation of the appropriate arene followed by bromination of the resulting ketone according to the similar procedure described in the literature. See for example: (a) Giordano, C.; Casagrande, F. Ger. Offen. DE 3006277, 4 Sep 1980, 26 pp, Chem. Abstr. 94:30372; (b) Carter, J. S.; Rogier, D. J.; Graneto, M. J.; Seibert, K.; Koboldt, C. M.; Zhang, Y.; Talley, J. Bioorg. Med. Chem. Lett. 1999, 9, 1167-1170.; (c) Almansa, C.; de Arriba, A. F.; Cavalcanti, F. L.; Gomez, L. A.; Miralles, A.; Merlos, M.; Garcia-Rafanell, J.; Forn, J. J. Med. Chem. 2001, 44, 350-361.
33. α-Bromoketones were prepared via Friedel-Crafts acylation of the appropriate arene followed by bromination of the resulting ketone according to the similar procedure described in the literature. See for example: (a) Giordano, C.; Casagrande, F. Ger. Offen. DE 3006277, 4 Sep 1980, 26 pp, Chem. Abstr. 94:30372; (b) Carter, J. S.; Rogier, D. J.; Graneto, M. J.; Seibert, K.; Koboldt, C. M.; Zhang, Y.; Talley, J. Bioorg. Med. Chem. Lett. 1999, 9, 1167-1170.; (c) Almansa, C.; de Arriba, A. F.; Cavalcanti, F. L.; Gomez, L. A.; Miralles, A.; Merlos, M.; Garcia-Rafanell, J.; Forn, J. J. Med. Chem. 2001, 44, 350-361.
34. Mechanistically, the reaction proceeds via in situ generation of the phenacyl ester followed by an intramolecular aldol-type condensation leading to the formation of the corresponding furanone, which subsequently can react with molecular oxygen to yield the product. See for example: Ref. 18 .
35. 24 (% inhibition was recorded @10 μM concentration of the drug). Selective inhibition of COX-2 over COX-1 is beneficial for the treatment of inflammatory diseases with reduced ulcerogenic side effects. See: Jackson, L. M.; Hawkey, C. J. Expert Opin. Invest. Drugs 1999, 8, 963-971.
36. Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., Chan C.-C. Inflamm. Res. 45:1996;68-74.